CytoSorbents to Present at the Life Sciences Forum on June 24, 2026 and Meet Virtually with Investors on June 30, 2026
Cytosorbents Corporation (CTSO) Q1 2026 Earnings Call Transcript
CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update
CytoSorbents to Report First Quarter 2026 Financial Results and Recent Business Highlights
Cytosorbents Corporation (CTSO) Q4 2025 Earnings Call Transcript
CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026
CytoSorbents to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results and Business Update
Cytosorbents Corporation (CTSO) Discusses Progress in Blood-Purification Programs and DrugSorb-ATR's Regulatory Path Transcript
CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025
Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London
Cytosorbents Corporation (CTSO) Q3 2025 Earnings Call Transcript
CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update
CytoSorbents to Participate at the Jefferies Global Healthcare Conference in London
CytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights
In Memoriam: Dr. Robert Hawes Bartlett (1939-2025) - Father of Extracorporeal Membrane Oxygenation (ECMO) and Former CytoSorbents Chief Medical Officer
CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen
CytoSorbents Provides DrugSorb-ATR Regulatory Update
CytoSorbents to Present at the H.C. Wainwright 27th Annual Global Investment Conference
CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR
Cytosorbents Corporation (CTSO) Q2 2025 Earnings Call Transcript
CytoSorbents Reports Second Quarter 2025 Financial Results and Provides Business Update
CytoSorbents Leads a New Era in Sepsis Treatment
CytoSorbents to Report Second Quarter 2025 Financial Results and Recent Business Highlights
CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR
CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb™-ATR
CytoSorbents to Participate at the Jefferies Global Healthcare Conference
CytoSorbents Therapy Significantly Reduces Bleeding in Urgent CABG Patients on Ticagrelor in New Data Presented at EuroPCR 2025
Cytosorbents Corporation (CTSO) Q1 2025 Earnings Call Transcript
CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update
CytoSorbents Provides Regulatory Update for DrugSorb-ATR
CytoSorbents to Report First Quarter 2025 Financial Results and Recent Business Highlights
CytoSorbents Receives Approximately $1.7 Million from the New Jersey Business Tax Certificate Transfer Program
CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller
CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America
CytoSorbents Extends Expiration Date of Outstanding Series B Right Warrants
Cytosorbents Corporation (CTSO) Q4 2024 Earnings Call Transcript
CytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit
CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller
CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue
CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week
CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India
Cytosorbents Corporation (CTSO) Q3 2024 Earnings Call Transcript
CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update
CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference
CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cytosorbents Corporation (CTSO) Q2 2024 Earnings Call Transcript